Locally Advanced NSCLC: Role of IO and Emerging Advances
Ticiana A. Leal, MD
9:15 AM
Panel Discussion
9:30 AM
Morning Symposium and Exhibits
Plenary 2: Early-Stage NSCLC
Moderators: Mohan Krishnamachary, MD, and Ticiana Leal, MD
10:15 AM
Neoadjuvant Therapy for Resectable NSCLC
Paul Bunn, MD
10:30 AM
Early-Stage NSCLC: When is Sub-Lobar Resection Appropriate?
Onkar Khullar, MD, MSc
10:45 AM
Adjuvant Therapy for Oncogene-Addicted NSCLC
Jamie E. Chaft, MD
11:00 AM
DEBATE: Should Adjuvant IO be Given After Surgery Following Chemo-IO
Yes: John V. Heymach, MD, PhD
No: Ryan Gentzler, MD
11:40 AM
Panel Discussion
11:55 AM
Lunch Symposium and Exhibits
Plenary 3: Targeted Therapy in Advanced NSCLC
Moderators: William S. Jonas, MD, and Jennifer W. Carlisle, MD
12:40 PM
EGFR Inhibition in Locally Advanced and Stage IV NSCLC
Suresh Ramalingam, MD, FACP, FASCO
12:55 PM
Treatment of ALK-Positive Advanced NSCLC
Shirish M. Gadgeel, MD
1:10 PM
KRAS Inhibition in Advanced NSCLC
John V. Heymach, MD, PhD
1:25 PM
Panel Discussion
1:40 PM
Afternoon Break and Exhibits
Plenary 4: Targeted Therapy in Advanced NSCLC II and Rare Thoracic Malignancies
Moderators: Paul Gill, MD, and Steven McCune, MD, PhD
2:00 PM
Liquid Biopsy: Current and Future Applications
Valsamo Anagnostou, MD
2:15 PM
EGFR Exon 20 Insertion and Uncommon EGFR Mutations
Jennifer W. Carlisle, MD
2:30 PM
RET, MET and ROS1: Optimal Therapy and Emerging Agents
Conor E. Steuer, MD
2:45 PM
Systemic Therapy for HER-2, BRAF and NTRK
Gregory J. Riely, MD, PhD
3:00 PM
Rare Thoracic Malignancies: Mesothelioma and Thymic Malignancies
Fatemeh Ardeshir, MD, MSc
3:15 PM
Panel Discussion
3:30 PM
Closing Remarks and Adjourn
We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.